Trust Co. of Vermont Takes Position in Thermo Fisher Scientific Inc. $TMO

Trust Co. of Vermont acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 50,515 shares of the medical research company’s stock, valued at approximately $25,326,000. Thermo Fisher Scientific comprises about 0.9% of Trust Co. of Vermont’s portfolio, making the stock its 28th biggest position.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $170,000. Raymond James Financial Inc. grew its stake in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after buying an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Lisa P. Britt sold 5,850 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock valued at $30,643,589 in the last 90 days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Up 0.8%

Thermo Fisher Scientific stock opened at $590.00 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The stock has a market cap of $218.15 billion, a P/E ratio of 31.74, a PEG ratio of 2.39 and a beta of 0.84. The firm’s fifty day moving average price is $533.64 and its 200-day moving average price is $508.36.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Barclays increased their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.